Skip to main content

Table 1 Epidemiological data of samples

From: ATRX immunostaining predicts IDH and H3F3A status in gliomas

Tumor WHO grade Samples (n) Recurrence (n) Sex (F/M) Age (mean, range)
Diffuse Astrocytoma   284 43 120/164 45 (5–81)
- Low grade (WHO II) II 136 14 61/75 43 (9–77)
- Anaplastic (WHO III) III 148 29 59/89 47 (5–81)
Oligoastrocytoma   71 23 29/42 43 (5–79)
- Low grade (WHO II) II 38 12 15/23 43 (5–79)
- Anaplastic (WHO III) III 33 11 14/19 43 (21–71)
Oligodendroglioma   83 32 44/39 48 (24–81)
- Low grade (WHO II) II 35 7 16/19 46 (24–81)
- Anaplastic (WHO III) III 48 25 28/20 50 (20–79)
Glioblastoma IV 415 57 169/246 57 (4–87)
- Primary IV 364 60 145/219 58 (4–87)
- Secondary IV 30 30 12/18 46 (26–68)
- With oligodendroglial component IV 13 3 3/10 61 (45–82)
- With PNET component IV 1 0 0/1 54
- Gliosarcoma IV 7 2 7/0 66 (53–75)
Ependymoma   112 25 50/62 41 (2–82)
- Low grade (WHO II) II 51 4 27/24 47 (2–82)
- Anaplastic (WHO III) III 26 11 11/15 35 (2–78)
- Myxopapillary I 24 8 7/17 36 (17–75)
- Subependymoma I 11 2 5/6 55 (44–75)
Pilocytic astrocytoma I 74 15 41/33 22 (2–78)
- Pilomyxoid (WHO II) II 2 1 1/1 8 (2–14)
- Anaplastic (WHO III) III 2 1 1/1 25 (24–25)